Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High-Risk for Psychosis.

ABSTRACT:

Background

Animal models indicate GABAergic dysfunction in the development of psychosis, and that benzodiazepine (BDZ) exposure can prevent the emergence of psychosis-relevant phenotypes. However, whether BDZ exposure influences the risk of psychosis in humans is unknown.

Methods

This observational-cohort study used electronic health record data from 818 individuals at clinical high-risk for psychosis (CHR-P) to investigate whether BDZ exposure (including hypnotics e.g., zopiclone) reduces the risk of developing psychosis and adverse clinical outcomes. Cox proportional-hazards models were employed in both the whole-unmatched sample, and a propensity score matched (PSM) subsample.

Results

567 CHR-P individuals were included after data cleaning (105 BDZ-exposed, 462 BDZ

SUBMITTER: Livingston NR 

PROVIDER: S-EPMC10462200 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature